P-322 Sarcopenia predicts outcomes in patients with hepatocellular carcinoma treated with atezolizumab and bevacizumab: A multicenter cohort study

The combination of atezolizumab and bevacizumab (A+B) is now the standard care for first-line systemic treatment unresectable hepatocellular carcinoma (HCC). This study aims to determine potential prognostic value sarcopenia inflammatory biomarker in predicting outcome A+B treatment. a retrospective, multi-center that includes consecutive HCC patients received from September 2020 December 2022. Pre-treatment computed tomography imaging was used measure cross-sectional area skeletal muscle at third lumbar vertebra, index (SMI) calculated by normalizing patient`s height. neutrophil-to-lymphocyte ratio (NLR) lymphocyte-to-monocyte (LMR) were as surrogate markers inflammation immune cell reservoir. associations factors on overall survival (OS) progression free (PFS) analyzed using Cox proportional hazards regression multivariable logistic models. included 150 patients, with median age 64 years, whom 85.3% male 69.3% classified having due viral hepatitis etiology. Sarcopenia found 41.3% while 50% had portal vein tumor thrombosis (PVTT), 60.7% extrahepatic spread (EHS). Median OS PFS 11.8 (95% CI, 7.9-23.0) 5.6 months 4.0-9.5), respectively. In response-evaluable (n = 131), objective response rate 35.1%. (HR, 2.027; 95% 1.172-3.506, p=0.012), NLR ≥3 1.879; 1.074-3.289, p=0.027), ALBI grade (≥2) 2.943; 1.031-8.398, p=0.044) PVTT 1.884; 1.040-3.411, p=0.037) independently associated OS. 1.774; 1.0.5-3.038, EHS 2.532; 1.352.5-4.741, p=0.004) independent predictors PFS. this multi-center, retrospective cohort provides evidence are important prognosis receiving Taking these into consideration can aid making decisions outcomes. Further research needed better identify high-risk or inflammation.